Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Adc Therapeutics Sa (ADCT)

Adc Therapeutics Sa (ADCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 411,586
  • Shares Outstanding, K 82,814
  • Annual Sales, $ 69,560 K
  • Annual Income, $ -240,050 K
  • 60-Month Beta 1.73
  • Price/Sales 5.57
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade ADCT with:

Options Overview Details

View History
  • Implied Volatility 99.34% ( -119.31%)
  • Historical Volatility 90.45%
  • IV Percentile 13%
  • IV Rank 7.41%
  • IV High 833.12% on 11/09/23
  • IV Low 40.64% on 01/25/24
  • Put/Call Vol Ratio 1.14
  • Today's Volume 45
  • Volume Avg (30-Day) 279
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 6,101
  • Open Int (30-Day) 5,705

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.58
  • Number of Estimates 3
  • High Estimate -0.53
  • Low Estimate -0.66
  • Prior Year -0.74
  • Growth Rate Est. (year over year) +21.62%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.07 +17.44%
on 03/27/24
5.38 -11.15%
on 04/08/24
+0.24 (+5.29%)
since 03/22/24
3-Month
2.13 +124.41%
on 01/25/24
6.04 -20.86%
on 02/20/24
+2.68 (+127.62%)
since 01/24/24
52-Week
0.36 +1,228.15%
on 11/13/23
6.04 -20.86%
on 02/20/24
+2.82 (+143.88%)
since 04/24/23

Most Recent Stories

More News
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC" or the "Company") (NYSE: ADCT). Such investors are...

ADCT : 4.78 (-3.82%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC" or the "Company") (NYSE: ADCT). Such investors are...

ADCT : 4.78 (-3.82%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC" or the "Company") (NYSE: ADCT). Such investors are...

ADCT : 4.78 (-3.82%)
Sobi to present new data at the 2023 EHA congress

/PRNewswire/ -- Sobi® will present data at the EHA (European Haematology Association) hybrid congress taking place in Frankfurt, Germany 8-11 June, 2023,...

ADCT : 4.78 (-3.82%)
ADC Therapeutics SA (ADCT) Reports Q1 Loss, Misses Revenue Estimates

ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of 7.50% and 5.49%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

ADCT : 4.78 (-3.82%)
ALIM : 3.63 (+1.11%)
ADC Therapeutics to Host First Quarter 2023 Financial Results Conference Call on May 9, 2023

ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, May 9, 2023 at 8:30 a.m. EDT to report financial results for the first quarter 2023 and...

ADCT : 4.78 (-3.82%)
Analysts Estimate ADC Therapeutics SA (ADCT) to Report a Decline in Earnings: What to Look Out for

ADC Therapeutics SA (ADCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ADCT : 4.78 (-3.82%)
NGM : 1.5400 (-1.28%)
PharmaVentures establishes an office in Seoul to enhance access for South Korean biotechs

/PRNewswire/ -- PharmaVentures announces its new office in Korea as part of its continued strategic expansion Headquartered in London, UK, PharmaVentures has...

ADCT : 4.78 (-3.82%)
Seres Therapeutics (MCRB) Moves 10.9% Higher: Will This Strength Last?

Seres Therapeutics (MCRB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase...

MCRB : 0.7295 (-4.01%)
ADCT : 4.78 (-3.82%)
ADC Therapeutics Releases its Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022

ADC Therapeutics SA (NYSE: ADCT) today announced its Annual Report on Form 20-F for the fiscal year ended December 31, 2022, has been filed with the U.S. Securities and Exchange Commission (the “SEC”)....

ADCT : 4.78 (-3.82%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

ADC Therapeutics SA is a late clinical-stage oncology-focused biotechnology company. It engages in development and commercialization of antibody drug conjugates for patients suffering from hematological malignancies and solid tumors. ADC Therapeutics SA is based in LAUSANNE, Switzerland.

See More

Key Turning Points

3rd Resistance Point 5.24
2nd Resistance Point 5.12
1st Resistance Point 4.95
Last Price 4.78
1st Support Level 4.66
2nd Support Level 4.54
3rd Support Level 4.37

See More

52-Week High 6.04
Last Price 4.78
Fibonacci 61.8% 3.87
Fibonacci 50% 3.20
Fibonacci 38.2% 2.53
52-Week Low 0.36

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar